A citation-based method for searching scientific literature

Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi, Takeharu Yamanaka, Allison Kemner, Debasish Roychowdhury, Jolanda Paolini, Tiziana Usari, Keith D Wilner, Koichi Goto. J Clin Oncol 2018
Times Cited: 129



Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li, Yerong Hu, Zhiping Tan, Matthew Stokes, Laura Sullivan, Jeffrey Mitchell, Randy Wetzel, Joan Macneill, Jian Min Ren, Jin Yuan, Corey E Bakalarski, Judit Villen, Jon M Kornhauser, Bradley Smith, Daiqiang Li, Xinmin Zhou, Steven P Gygi, Ting-Lei Gu, Roberto D Polakiewicz, John Rush, Michael J Comb. Cell 2007
Times Cited: 1627




List of shared articles



Times cited

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
22


Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
3

Different clinical features between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer.
Xianxiu Ji, Huikang Xie, Ren Zhu, Bin Chen, Sen Jiang, Jie Luo. J Int Med Res 2021
0

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, Viola W Zhu, Ted W Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R Digumarthy, Charlotte Lee, Andrew Do,[...]. Clin Cancer Res 2021
2

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
2

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
4

ROS1 Targeted Therapies: Current Status.
Christine M Azelby, Mandy R Sakamoto, Daniel W Bowles. Curr Oncol Rep 2021
2

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
8

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou,[...]. BMC Med 2021
0


Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Lucia Trudu, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Massimo Dominici,[...]. Int J Mol Sci 2021
0

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Subba R Digumarthy, Dexter P Mendoza, Jessica J Lin, Tianqi Chen, Marguerite M Rooney, Emily Chin, Lecia V Sequist, Jochen K Lennerz, Justin F Gainor, Alice T Shaw. Clin Lung Cancer 2020
12

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma.
Shinkichi Takamori, Takashi Seto, Mikako Jinnouchi, Taro Oba, Masafumi Yamaguchi, Mitsuhiro Takenoyama. Ther Clin Risk Manag 2020
2


Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Haiyan Xu, Quan Zhang, Li Liang, Junling Li, Zhefeng Liu, Weihua Li, Lu Yang, Guangjian Yang, Fei Xu, Jianming Ying,[...]. Cancer Med 2020
6

Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
Jing Zheng, He Cao, Yuping Li, Chuangzhou Rao, Te Zhang, Jiayou Luo, Dongqing Lv, Yanping Zhu, Jianya Zhou, Jianying Zhou. Lung Cancer 2020
3

Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Meiying Cui, Yuchen Han, Pan Li, Jianying Zhang, Qiuxiang Ou, Xiaoling Tong, Ruiying Zhao, Nan Dong, Xue Wu, Wencai Li,[...]. Mol Oncol 2020
3

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
10

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
3


Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer.
Qing Zhang, Chunyan Wu, Wei Ding, Zhihong Zhang, Xueshan Qiu, Dianbin Mu, Haiqing Zhang, Yanfeng Xi, Jianhua Zhou, Liheng Ma,[...]. Thorac Cancer 2019
11


Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer.
You-Cai Zhu, Xin-Gen Zhang, Xue-Ping Lin, Wen-Xian Wang, Xiao-Feng Li, Li-Xin Wu, Hua-Fei Chen, Chun-Wei Xu, Kai-Qi Du. Oncol Lett 2019
6


ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes.
Amit Joshi, Nikhil Pande, Vanita Noronha, Vijay Patil, Rajiv Kumar, Anuradha Chougule, Vaishakhi Trivedi, Amit Janu, Abhishek Mahajan, Kumar Prabhash. Ecancermedicalscience 2019
7

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib.
Yueming He, Wang Sheng, Weiguo Hu, Jing Lin, Junjun Liu, Bing Yu, Xinru Mao, Lu Zhang, Jin Huang, Guangsuo Wang. Oncol Res 2019
11

Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
Chang Liu, Hui Yu, Jianhua Chang, Haiquan Chen, Yuan Li, Weixin Zhao, Kuaile Zhao, Zhengfei Zhu, Si Sun, Min Fan,[...]. Target Oncol 2019
9

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari,[...]. Ann Oncol 2019
89